Ziprasidone의 자연적 임상경험에 대한 후향적 조사 연구 : 3개 대학병원의 경험
Naturalistic, Retrospective Study on Clinical Experience of Ziprasidone in 3 University Hospitals
0
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
본 연구는 후향적 방법을 통해 ziprasidone의 자연적인 임상적 경험을 평가하고자 하였다. 주요 소견으로 ziprasidone은 일차선택약제로 보다는 기존 항정신병약물의 교체시 주로 사용되어졌으며, 기존 약제의 불충분한 치료효과 및 부작용, 특히 체중증가가 주된 교체사유였다. 임상적 호전에 있어서는 CGI-I 점수상 약간 또는 상당한 호전을 보였으며, 안정성 면에서 ziprasidone 교체 후 의미있는 체중감소를 보였고, QT 간격의 연장에 있어서도 1예를 제외하고는 QT 간격의 의미있는 변화는 보이지 않았다. 그러나 추체외로부작용은 기존 보고보다 다소 높은 빈도로 경험하고 있는 것으로 나타났다.
Abstract
Objectives: This naturalistic retrospective study investigated the effectiveness of ziprasidone as measured by mean improvements of the Clinical Global Impression (CGI-I). Secondary objectives included prescribing patterns, tolerability, and safety. Methods: From May to July 2006, 98 psychiatric patients who have been taking ziprasidone for at least 2 weeks were selected. Their current clinical statuses were assessed by the interview, laboratory tests including electrocardiogram (ECG). Data on DSM-IV diagnoses, dosing, concomitant psychotropic medications, clinical changes, adverse effects, and laboratory findings were collected retrospectively. Results: Ziprasidone was mostly prescribed to switch previous antipsychotics for the treatment of schizophrenia. Two main reasons for switch were unsatisfactory efficacy and poor tolerance, especially weight gain, of the preceding antipsychotic medication. Participants as a whole showed mean 2.7±1.0 of the CGI-Improvement. Significant weight reduction after switching to ziprasidone was occurred, which was related to the clinical improvement. No significant increase of the QTc interval except one case was observed. Conclusion: The present study confirmed previous tolerability and safety data of ziprasidone as well as the results of its effectiveness.
참고문헌 (32)
- "Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial", 65, pp.1624~1633 (2004)
- "Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia", 162, pp.1535~1538 (2005)
- "Ziprasidone in the acute treatment of schizophrenia", 16(3), pp.13~19 (2005)
- "Ziprasidone 80 mg", day and 160 mg, pp.1999, 20[DOI]
- "The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia", 61, pp.4~9 (2000)
- "Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder", 65, pp.217~221 (2004)
- "Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial", 160, pp.741~748 (2003)
- "Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial", 25, pp.301~310 (2005)
- "A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg", day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study, 2002, pp.17, 207~215
- "Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine", 20, pp.105~112 (2005)
- "Schizophrenia and obesity: impact of antipsychotic medications", 65, pp.13~26 (2004)
- "FDA background on ZeldoxTM (ziprasidone hydrochloride capsules)" (2000), Pfizer, Inc.
- "Ziprasidone in the management of schizophrenia", 17, pp.423~430 (2003)
- "Torsades de pointes associated with ziprasidone", 47, pp.264~268 (2006)
- "Factors in antipsychotic drug selection: tolerability consideratioins", 8, pp.23~25 (2003)
- "Antipsychotic drugs and QT prolongation", 20, pp.243~251 (2005)
- "Diagnostic and statistical manual of mental disorders: DSM-IV." (2000), Washington DC: American Psychiatric Association
- "ECDEU assessment manual for psychopharmacology- revised", pp.217~222
- "The efficacy of ziprasidone on bipolar disorder", 16(3), pp.45~52 (2005)
- "GEODON (ziprasidone HCL) prescribing information." (2006)
- "Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder", 62, pp.1217~1251 (2002)
- "Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: Results of a multi-centre observational trial" (2007)
- "Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications", 51, pp.502~511 (2006)
- "(2001) Antipsychotic-associated weight gain and clinical outcome parameters", 62, pp.11~21 (2001)
- "Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol", 187, pp.537~543 (2005)
- "A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia", 63, pp.516~523 (2002)
- "Ziprasidone 40 and 120 mg", day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial, 1998, pp.140, 173~184
- "Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder", 161, pp.1837~1847 (2004)
- "Risperidone and olanzapine drug outcomes study in Korean patients with schizophrenia and schizoaffective disorder", 43, pp.232~245 (2002)
- "Efficacy and safety of olanzapine in the treatment of Korean patients with schizophrenia ans achizophreniform disoder", 40, pp.693~707 (2004)
- "Efficacy and safety profile of risperidone in schizophrenia", 37, pp.60~74 (1998)
- "Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia", 21, pp.21~28 (2006)